Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results
Date:8/12/2008

on technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to our late stage clinical programs. Actual results may differ materially from current expectations based on risks and uncertainties affecting MAP Pharmaceuticals' business, including, without limitation, risks and uncertainties relating to the enrollment and conduct of clinical trials, as well as risks related to the failure to achieve favorable clinical outcomes and that our product candidates will not be approved for commercial use by the U.S. Food and Drug Administration. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2008, and available at http://edgar.sec.gov .

CONTACT: Christop
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Triax Pharmaceuticals Launches New Mid-Potency Corticosteroid Vehicle, Locoid Lotion 0.1%
2. ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update
3. Novis Pharmaceuticals Announces John W. Kilgour as Executive Vice-President of Sales & Marketing
4. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
5. Alseres Pharmaceuticals to Host 2008 Second Quarter Conference Call
6. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 “Have you recently been involved ... and personal injury lawyer serving the greater Seattle area. “Are ... so, then keep reading . , In a recently ... in an auto accident can use to see if they ... a personal injury insurance claim will allow an individual to ...
(Date:8/20/2014)... The “Human Insulin Market by Product ... Modern Human Insulin (Rapid Acting, Long Acting, Premixed)], ... Others) - Forecast to 2019” provides a detailed ... market trends,and strategies impacting the global human insulin ... the revenue and share analysis. , Browse 110 ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Mixberry Media ... speech-enable their websites and create a new source of ... consume content by listening to a narration of their ... reader genders and languages. Users can now multitask: ... social networks, while consuming content. , Mixberry ...
(Date:8/20/2014)... August 20, 2014 Over 31 million Americans ... of Disease, low back pain is the single leading cause ... reasons for missed work. Americans spend at least $50 billion ... Most cases of back pain are not due to organic ... , For example, Pete, a busy accountant, had little time ...
(Date:8/19/2014)... in Houston, Texas, is pleased to announce it is now ... with old fillings that need replacing, will benefit from the ... teeth. , From now on any cavities will be repaired ... amalgam free. Even though amalgam fillings have been deemed as ... children over the age of six, they do contain mercury ...
Breaking Medicine News(10 mins):Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Physical Therapists Learn to Relieve Low Back Pain 2Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... New Rochelle, NY, August 6, 2009The more time college ... to feel jealous toward their romantic partners, leading to ... will further fuel their jealousy, in an escalating cycle ... in CyberPsychology & Behavior , a peer-reviewed journal ...
... Gene signature detects differences in viral, bacterial infections, ... -- A genomic "signature" in blood appears able to ... viruses, such as the cold or flu, even before ... volunteers who were infected with either a live cold ...
... , , , ... Board: PSTX) today announced record quarterly revenues. , , ... Steven H. Kane, Chief Executive Officer of Patient Safety Technologies. ... adopting the Safety Sponge((TM)) System as the solution to the problem ...
... SOUTH PASADENA, Calif., Aug. 6 California Cancer ... center in South Pasadena. The 22,000 s.f. facility, operating under ... in medical, surgical and radiation oncology. In addition, ... San Gabriel Valley to offer RapidArc((TM)), a new and highly ...
... STAMFORD, Conn., Aug. 6 The Purdue Products L.P. ... the National Association of Chain Drug Stores (NACDS) 2009 Marketplace Conference, ... and the primary ingredient is the deseeded pod of the senna ... ) , , "We,ve always ...
... , Report Shows That Making Americans ... , , SAN DIEGO, Aug. 6 As ... decline in public support for health reform efforts, new research shows ... moving the reform needle. , , The ...
Cached Medicine News:Health News:Does Facebook usage contribute to jealousy in relationships? 2Health News:Cold, Flu or Pneumonia? Answer May Lie in Blood Test 2Health News:Patient Safety Technologies Reports Second Quarter Results 2Health News:Patient Safety Technologies Reports Second Quarter Results 3Health News:Patient Safety Technologies Reports Second Quarter Results 4Health News:Patient Safety Technologies Reports Second Quarter Results 5Health News:Patient Safety Technologies Reports Second Quarter Results 6Health News:Patient Safety Technologies Reports Second Quarter Results 7Health News:California Cancer Specialists Medical Group, Inc. Opens Outpatient Cancer Center in South Pasadena, Calif., With Renowned Medical Staff, State-of-the-Art Technology 2Health News:Senokot(R) Tablets Undergo a Natural Makeover 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 2Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 3Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 4Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 5Health News:New Research Suggests Most Are Willing to Make Tradeoffs and Would Embrace Comprehensive Health Care Reform 6
(Date:8/19/2014)... -- Talyst, a market leader in pharmacy automation and ... Summer Conference in Las Vegas, NV. ... products and services.   Talyst is the ... customers with a variety of software and services. Talyst ... solution, AutoSplit® Contract Pharmacy and 340B Compliance Services. AutoSplit ...
(Date:8/19/2014)... , Aug. 19, 2014  As power morcellator ... country, Bernstein Liebhard LLP notes that women in ... between a number of options that do not ... instrument. According to a report published by The ... these options include a mini-laparotomy and vaginal hysterectomy. ...
(Date:8/19/2014)... RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ ... and Drug Administration (FDA) accepted for review the ... (FDC) of tiotropium and olodaterol delivered via the ... of long-term, once-daily maintenance treatment of airflow obstruction ... including chronic bronchitis and/or emphysema. Tiotropium + olodaterol ...
Breaking Medicine Technology:Talyst Exhibits at the NPPA Summer Conference 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... , NEW YORK, Dec. 2 Reportlinker.com ... in its catalogue: , Cardiovascular Devices: Technologies ... , Offer a comprehensive view of the cardiovascular devices ... of the major types of cardiovascular diagnostic equipment, including ...
... , ... new market research report is available in its catalogue: ... Trends , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The ... a flurry of activity with pharmaceutical companies adding chiral ...
Cached Medicine Technology:Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 2Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 3Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 4Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 5Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 6Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 7Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 8Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 9Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 10Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 11Reportlinker Adds Cardiovascular Devices: Technologies and Global Markets 12Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5
... provides the most useful measurement for ... states. It is the preferred diagnostic ... patients who have experienced changes in ... dehydration. It is also used to ...
... HemoCue Hemoglobin Test Systems ... reliable quantitative hemoglobin results ... as a large hematology ... consists of either the ...
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: